Skip to main content

Table 3 Potency conversion of DOAC

From: Profiles of direct oral anticoagulants and clinical usage—dosage and dose regimen differences

  Rivaroxaban Dabigatran Apixaban Edoxaban
Molecular weight (Da) 436 628 460 548
(a) Molecular weight ratio to rivaroxaban 1 1.44 1.06 1.26
Bioavailability (%) 90*a 6.5 66 47.5*c
(b) Bioavailability ratio to rivaroxaban 1 13.85 1.36 1.89
Protein binding (%) 93.5*b 35 87 49.5*d
(c) Protein-binding ratio to rivaroxaban 1 0.37 0.93 0.53
Inhibitory constant; Ki (nM) 0.4 4.5 0.08 0.56
(d) Ki ratio to rivaroxaban 1 11.25 0.20 1.40
(A) Total ratio to rivaroxaban = (a)X(b)X(c)X(d) 1 83.99 0.27 1.77
(B) SPAF customary daily dose (mg) 20 300 10 60
Potency conversion; matching dose for customary dose of rivaroxaban (B)/(A) 20 3.57 37.35 33.99
(C) SPAF reduced daily dose (mg) 15 220 5 30
Potency conversion; matching dose for reduced dose of rivaroxaban (C)/(A) 15 2.62 18.68 17.00
  1. *Average from a80–100, b92–95, c45–50, d40–59
  2. SPAF stroke prevention in atrial fibrillation, Ki inhibitory constant